American journal of epidemiology · 2025
The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Botta Laura, Capocaccia Riccardo, Bernasconi Alice, Rossi Silvia, Galceran Jaume, Dal Maso Luigino, Lepage Come, Molinié Florence, Bouvier Anne-Marie, Marcos-Gragera Rafael, Vener Claudia, Guevara Marcela, Murray Deirdre, Ragusa Rosalia, Gatta Gemma, Jooste Valerie, EUROCARE-6 WG
Аннотация
Relative survival (RS) with the general population as the reference is commonly used to estimate net survival (NS). However, cancer patients may face an increased risk of noncancer death compared to cancer-free individuals. We evaluate the impact of considering this relative risk (RR) on NS estimation. First, we compared selected NS values to generated RS under various theoretical scenarios, considering different RR, NS, age at diagnosis, time since diagnosis, and sex. Then, differences between NS and RS for 3 cancers were analyzed from cure model-based estimates using EUROCARE-6 data. We observed differences between RS and the true value of NS, larger for longer time since diagnosis, older patients, and higher NS. For head and neck cancer, the smallest differences were for young female patients at 5 years from diagnosis (4%) and the highest (32%) for older patients. For colorectal cancer, differences were <7% for all ages, both sexes, and times since diagnosis and for breast cancer, differences were <5% except for older patients after 5 years. If RR > 1, RS underestimates NS. Our findings aim to correctly interpret the differences between RS and NS, and contextualize the possible biases of assuming RS as a proxy for cancer-specific survival.